Société Foamix Pharmaceuticals Ltd. Nasdaq
Actions
IL0011334385
Produits pharmaceutiques
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01/03/20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/03/20 |
Mutya Harsch
LAW | General Counsel | 50 | 01/03/20 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10/09/20 |
Steven Basta
BRD | Director/Board Member | 59 | 01/01/15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01/03/20 |
Director/Board Member | 62 | 01/03/19 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 01/03/20 |
Director/Board Member | - | 01/01 | |
Sharon Barbari
BRD | Director/Board Member | 70 | 01/03/20 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 14 098 888 | 12 874 235 ( 91,31 %) | 0 | 91,31 % |
Coordonnées société
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+25,83 % | 661 Md | |
+27,00 % | 566 Md | |
-6,76 % | 352 Md | |
+20,34 % | 332 Md | |
+3,00 % | 283 Md | |
+13,09 % | 231 Md | |
+5,46 % | 200 Md | |
-9,61 % | 195 Md | |
-6,26 % | 145 Md |